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Abstract
Objective: To study the roles of self-reported symptoms and/or prior diagnosis of 
polycystic ovary syndrome (PCOS) and other potential risk factors for gestational 
diabetes mellitus (GDM) and to clarify whether the screening of GDM in early pregnancy 
is beneficial for all women with PCOS.
Design: The FinnGeDi multicentre case-control study including 1146 women with 
singleton pregnancies diagnosed with GDM and 1066 non-diabetic pregnant women. 
There were 174 women with PCOS (symptoms and/or diagnosis self-reported by a 
questionnaire) and 1767 women without PCOS (data missing for 271).
Methods: The study population (N = 1941) was divided into four subgroups: GDM + PCOS 
(N = 105), GDM + non-PCOS (N = 909), non-GDM + PCOS (N = 69), and controls (N = 858). The 
participants’ characteristics and their parents’ medical histories were compared.
Results: The prevalence of PCOS was 10.4% among GDM women and 7.4% among non-
diabetics (odds ratios (OR) 1.44, 95% CI: 1.05–1.97), but PCOS was not an independent 
risk for GDM after adjustments for participants’ age and pre-pregnancy BMI (OR 1.07, 
95% CI: 0.74–1.54). In a multivariate logistic regression analysis, the most significant 
parameters associated with GDM were overweight, obesity, age ≥35 years, participant’s
mother’s history of GDM, either parent’s history of type 2 diabetes (T2D) and 
participant’s own preterm birth.
Conclusions: The increased risk of GDM in women with PCOS was related to obesity 
and increased maternal age rather than to PCOS itself, suggesting that routine early 
screening of GDM in PCOS women without other risk factors should be reconsidered. 
Instead, family history of GDM/T2D and own preterm birth were independent risk factors 
for GDM.
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Introduction
Gestational diabetes mellitus (GDM) and polycystic 
ovary syndrome (PCOS) are the most common endocrine 
disorders in women of reproductive age. The prevalence 
of GDM varies from 9% to 25% and the prevalence of 
PCOS varies from 5% to 15%, depending on the study 
populations and the diagnostic criteria applied (1, 2, 3, 
4, 5). Both disorders are associated with insulin resistance 
and overweight/obesity (6, 7). Also, genetic factors play a 
significant role in both conditions (8, 9).
GDM and PCOS can be early signs of an increased 
risk of manifest diseases related to insulin resistance, 
such as type 2 diabetes (T2D), and both disorders are 
also connected with cardiovascular risk factors, such as 
metabolic syndrome, hypertension and dyslipidaemia 
(1, 10, 11, 12, 13, 14). While similar metabolic risks are 
associated with these conditions, the independent role 
of PCOS and the roles of shared risk factors for GDM 
are still unclear. Several studies have shown that PCOS 
increases the risk for GDM independent of the degree 
of adiposity (2, 15, 16, 17, 18). Mikola et al. found that 
PCOS independently increased the risk of GDM, but 
that overweight was the strongest predictor for GDM 
(19). However, another study reported that non-obese 
women with PCOS were not at risk for GDM (20). Also, 
two studies including participants matched for BMI and 
age did not report increased risk for GDM in women 
with PCOS (21, 22). Despite these inconsistent data, in 
Finland, PCOS is considered an independent indication 
for an early oral glucose tolerance test (OGTT) during 
pregnancy, regardless of BMI, according to the 2008 
National Current Care Guidelines (23). In the present 
study, we aimed to test the validity of this practice 
further and to clarify the role of PCOS as a risk factor 
for GDM.
In this case–control setting, our first aim was, 
therefore, to investigate whether PCOS is an independent 
risk factor for GDM. This information is important to 
clarify whether the performance of an early OGTT is 
necessary for all pregnant women with PCOS regardless 
of their BMI. Second, we wanted to investigate the role 
of other shared risk factors for PCOS and GDM, such as 
overweight or obesity, the woman’s own birth data and 
current characteristics and her parents’ medical histories. 
To clarify these issues, we divided the study population 
into four subgroups according to GDM and PCOS status. 
We hypothesised that participants displaying both 
disorders would share more risk factors compared to 
controls or those with only one disorder.
Subjects and methods
Participants
The Finnish Gestational Diabetes Study (FinnGeDi study) 
aims to study genetic and environmental factors linked 
to the development of GDM and has two arms: a register-
based (5, 24) and a clinical genetic arm. The present 
case–control study was based on the clinical genetic arm, 
which was piloted at Oulu University hospital (tertiary-
level) in February 2009 and extended after 3 months to six 
other hospitals (Helsinki and Uusimaa, Central Finland, 
Satakunta, Southern Ostrobothnia, Southern Karelia and 
Kainuu), each serving a geographically based catchment 
area. Recruitment ended in December 2012. Women with 
GDM and a singleton pregnancy (N = 1115) were recruited 
in delivery units before delivery, and the next consenting 
mother without GDM (N = 1125) giving birth in the same 
hospital was recruited as a control. The spouses and new-
borns of both GDM and non-diabetic mothers were also 
included in the study. The GDM status of all participants 
was confirmed by their medical records: 12 women with 
pre-pregnancy diabetes were excluded. Sixteen women 
were recruited during two pregnancies, and their latter 
pregnancy was excluded. In total, 1146 women fulfilled 
the GDM criteria, and 1066 women were defined as non-
diabetic controls (Fig. 1).
Clinical data
After recruitment, the participants were asked to complete 
a detailed questionnaire about their medical and family 
history and lifestyle. This questionnaire also included 
questions on oligomenorrhoea, the presence of hirsutism 
and prior diagnosis of PCOS. In total, 1030 (89.9%) 
GDM and 935 (87.7%) non-diabetic women returned 
the questionnaire. Comprehensive, detailed data on 
pregnancy and delivery were collected from the hospital 
and maternal welfare clinic records by trained research 
nurses and medical students. Clinical data from the 
questionnaire and medical records were supplemented 
by individually linked register data obtained from the 
Finnish Medical Birth Register (MBR). In Finland, all 
live births and stillbirths of infants weighing ≥500 g 
or having a gestational age of ≥22  weeks are reported 
to the MBR. A structured form is completed by the 
delivery hospital within one week after delivery. The 
MBR includes detailed information about the pregnancy, 
delivery and perinatal health of the new-borns until the 
age of seven days.
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Definitions
Women with GDM
Gestational diabetes was diagnosed by a 2-h 75 g OGTT 
after overnight fasting. According to the 2008 National 
Current Care Guidelines, OGTT was recommended for 
every pregnant woman, excluding women with very low 
risk for GDM: (1) primiparous women of normal weight 
(BMI <25 kg/m2) who were under 25 years of age and had 
no family history of diabetes, and (2) multiparous women 
of normal weight (BMI <25 kg/m2) who were under 
40 years of age and had no history of GDM or macrosomic 
births (birth weight over 4500 g) (23).
OGTT was mainly performed between the 24th and 
28th weeks of pregnancy and was recommended between 
the 12th and 16th gestational weeks in cases with a high 
risk of GDM (prior GDM, BMI ≥35 kg/m2, glucosuria, 
family history of T2D or PCOS). Of note, in Finland, 
PCOS is an independent indication for early OGTT 
during pregnancy. If the first OGTT was normal, it was 
repeated between the 24th and 28th weeks of gestation. 
The cut-off values for plasma glucose concentrations 
were ≥5.3 mmol/L after fasting, ≥10.0 mmol/L at 1 h and 
≥8.6 mmol/L at 2 h after glucose intake. A diagnosis was 
made if one or more values in the OGTT were abnormal 
(23). Additionally, GDM diagnosis was based on glucose 
self-monitoring for 24 participants. Of these participants, 
20 (83.3%) started early self-monitoring because of a 
previous history of GDM, and four (16.7%) because of 
unsuccessful OGTT testing. All of them had blood glucose 
values repeatedly over the target range (fasting glucose 
≥5.5 mmol/L and 1 h after meal ≥7.8 mmol/L). Of these 
participants, 13 (54.2%) were treated with insulin, ten 
with diet (41.7%) and one (4.2%) with metformin.
Women with self-reported symptoms and/or prior 
diagnosis of PCOS
Because the study was performed at the time of delivery, the 
definition of PCOS was based on a self-reported questionnaire 
that included a question on whether the participant had been 
diagnosed with PCOS and questions regarding excessive body 
hair and oligomenorrhoea before pregnancy. The criteria for 
oligomenorrhoea (‘Menstrual cycle often (more than twice a 
year) more than 35 days without hormonal contraception’) 
had been validated in our previous studies performed in a 
large Finnish population-based follow-up cohort (25, 26). 
Additionally, women with irregular menses (N = 97), defined 
as a difference frequently exceeding 7  days between the 
longest and shortest menstrual cycles, were included in 
the oligomenorrhoea group. Hirsutism was assessed if a 
woman reported excessive body hair or removed facial 
hair at least four times per month. Again, the validity of 
this questionnaire to detect women with typical endocrine 
Figure 1
Flow chart of study population. GDM, gestational diabetes mellitus; PCOS, polycystic ovary syndrome. *20 women recruited as GDM cases but confirmed 
by medical record review to have normal glucose tolerance during pregnancy. **72 women recruited as a control fulfilled the criteria for GDM by 
medical record review. 1Confirmed status of participant, with diagnosis of GDM based on oral glucose tolerance test result(s) (n = 1122) or self-
monitoring (n = 24) and the absence of type 1 or 2 diabetes as indicated by medical record review.
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characteristics of PCOS has been shown in our previous 
studies (25, 26).
There were 521 (26.8%) participants with 
oligomenorrhoea or irregular menses, 207 (10.7%) with 
hirsutism and 87 (4.5%) with both a menstrual disorder and 
hirsutism. Also, 124 (6.4%) participants reported a prior PCOS 
diagnosis and 37 (1.9%) reported both a prior diagnosis and 
two symptoms. Hence, in total, 174 participants with both 
symptoms and/or prior diagnosis were considered to have 
PCOS. The controls for the PCOS group included the 1767 
participants without two symptoms and without a diagnosis 
of PCOS. The participants with missing data regarding PCOS 
symptoms were excluded from the study (N = 271).
The study population (N = 1941) was then divided 
into four subgroups: GDM + PCOS (N = 105), GDM + non-
PCOS (N = 909), non-GDM + PCOS (N = 69) and controls 
(N = 858) (Fig. 1). Women with GDM, PCOS or both were 
compared with controls.
Measures
The questionnaire obtained the participant’s birth weight 
and gestational age at birth. Preterm birth was defined 
as gestational age <37 + 0  weeks. Two participants were 
excluded from the birth weight analyses because they 
reported abnormally high birth weights for the length 
of gestation (<37 gestational weeks with >3 s.d.s of birth 
weight, according to Finnish standards) (27). Small-for-
gestational age (SGA) participants were defined as those 
with a birth weight of <−2 s.d.s and large-for-gestational-
age participants as those with a birth weight of >+2 s.d.s. 
BMI was calculated from participants’ pre-pregnancy 
height and weight (kg/m2), which were obtained from 
maternity welfare clinic records. BMIs between 18.5 kg/m2 
and 24.9 kg/m2 were classified as normal, those between 
25.0 kg/m2 and 29.9 kg/m2 as overweight and those of 
30.0 kg/m2 or more as obese (28).
The educational attainment of each participant was 
obtained from the questionnaire and categorised as basic 
or less, secondary, lower-level tertiary or upper-level 
tertiary. When education was not reported (three cases), 
it was deduced based on the MBR data about the mother’s 
occupation during pregnancy. Data about smoking before 
pregnancy were obtained from the questionnaire and data 
about smoking during pregnancy were obtained from the 
MBR. Information on participants’ previous pregnancies 
was obtained from the MBR and questionnaire. 
Participants’ parents’ education and medical histories, 
including histories of diabetes and cardiovascular 
morbidity, were taken from the questionnaire.
Statistical methods
Data were analysed with SPSS 22.0 (IBM SPSS Statistics for 
Macintosh, version 22.0. Armonk, NY, USA: IBM Corp.). 
The subgroups were dummy-coded for statistical analysis, 
with controls used as references. One-way ANOVA was 
used for continuous variables and chi-square tests for 
categorical variables. Continuous variables are reported 
as mean ± s.d. and categorical variables are reported as 
frequencies (%). Normal probability plots and visual 
inspection of histograms were used to assess normality and 
no transformations were considered necessary. Statistical 
significance was set at a two-sided P value of <0.05. Linear 
regression (mean differences with 95% CI) was used for 
continuous variables, and logistic regression (odds ratios 
(ORs) with 95% CI) was used for categorical variables. 
Multiple regression models were used. The first model was 
unadjusted (crude). The effect of adding each variable in 
sequence was evaluated before fitting the final model. The 
final model was adjusted for participant’s parity, smoking 
during pregnancy, educational attainment, delivery 
hospital, age and pre-pregnancy BMI. Interactions with 
PCOS and the covariates were tested by adding the 
product term between the two variables of interest in 
the regression model to the variables of interest and were 
found to be non-significant.
Covariates
Covariates in this study were participant’s age, pre-
pregnancy BMI, parity, educational attainment, smoking 
during pregnancy and delivery hospital. Participant’s age, 
pre-pregnancy BMI and parity were included because 
these potential confounding factors may reflect the 
course of pregnancy. Educational attainment was used as 
an indicator of socio-economic status (SES) since there is 
evidence that low childhood SES may be associated with 
PCOS (29). There may also be an association between 
smoking during pregnancy and GDM (30). The delivery 
hospital was observed to minimise the potential risk 
that local practices could differ between hospitals. When 
the present characteristics of participants were studied, 
these covariates acted as potential confounders. When 
participants’ characteristics at birth and medical histories 
of participants’ parents were assessed, the covariates were 
potential mediators.
Ethical approval
The study protocol was approved by the Ethics Committee 
of the Northern Ostrobothnia Hospital District in 2009. 
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Each participant gave written informed consent after full 
explanation of the purpose and nature of all procedures 
used. The National Institute for Health and Welfare (THL) 
permitted the use of MBR data in this study.
Results
The prevalence of self-reported symptoms and/or prior 
diagnosis of PCOS was 10.4% among GDM women and 
7.4% among non-diabetic women (OR 1.44, 95% CI: 
1.05–1.97) (Model 1). The difference remained significant 
after adjusting for parity, smoking during pregnancy, 
educational attainment and delivery hospital (Model 
2) (OR 1.47, 95% CI: 1.07–2.02), but disappeared after 
further adjustments for age and pre-pregnancy BMI 
(OR 1.07, 95% CI: 0.74–1.54) (Model 5), suggesting that 
PCOS is not an independent risk factor for GDM (Fig. 2). 
The results remained similar regardless of whether the 
definition of PCOS was based on symptoms or prior 
diagnosis. Moreover, the exclusion of the participants 
with an isolated PCOS symptom from the control group 
did not affect the results. Further, the results did not 
change after excluding participants with GDM diagnosed 
by self-monitoring (N = 24).
Participants’ birth
Participants who were themselves born with a lower birth 
weight had a higher risk of GDM regardless of the presence 
of PCOS (Tables 1 and 2). This association was mostly due 
to slower foetal growth, as indicated by a lower s.d. score 
for birth weight. No linear association was observed with 
participant’s own gestational age, but participants born 
preterm had a two-fold risk of GDM (Table 3).
Participants in the non-GDM + PCOS group were born, 
on average, 0.5 weeks later than the controls (Tables 1 and 
2). Participants with both GDM + PCOS were born three 
times as often SGA than the controls (P = 0.013). This 
finding was not related to participants’ pre-pregnancy BMI.
Participants’ educational attainment and health
Participants with GDM, regardless of PCOS status, were 
less educated in comparison to controls (P = 0.012). Lower 
educational attainment correlated with higher pre-
pregnancy BMI (P < 0.001). In addition, participants with 
GDM, regardless of PCOS status, were significantly older 
(P < 0.001) and more often had three or more previous 
pregnancies (P = 0.001) and deliveries (P = 0.014) than the 
controls (Table 1).
Participants with GDM were shorter and had higher 
pre-pregnancy BMI than controls (Tables  1 and 2). A 
difference in height was present in both the GDM + PCOS 
(−0.5 cm) and GDM + non-PCOS (−0.6 cm) groups but was 
statistically significant only in the latter. Pre-pregnancy 
BMI was significantly higher in the GDM + PCOS group 
compared to the other three groups, and participants in 
this group were more likely to be obese (Fig. 3). The results 
did not change after adjusting for participants’ parity, 
smoking during pregnancy, educational attainment, 
delivery hospital and age (Tables 1 and 2).
Figure 2
Odds ratios (ORs) for gestational diabetes mellitus 
(GDM) in women with polycystic ovary syndrome 
(PCOS) calculated by logistic regression (N = 174).
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Medical histories of participants’ parents’
The participant’s risk for GDM was doubled if her mother 
had a history of GDM or T2D (Tables 3, 4 and 5). If the 
participant’s father had a history of T2D, the participant’s 
risk for GDM was 1.4-fold. If either of a participant’s 
parents had a history of hypertension, her risk for GDM 
was 1.5-fold. The result was, however, non-significant 
after adjusting for pre-pregnancy BMI. Parental diabetes 
and other cardiovascular morbidities were not associated 
with the presence of PCOS.
Risk factors for GDM
In the multivariate regression analyses, the most significant 
parameters independently associated with participant’s 
GDM were adiposity, age (≥35 years), own preterm birth, 
participant’s mother’s history of GDM or either parent’s 
history of T2D (Table  3). In total, 27 (26.0%) of the 
women with GDM + PCOS and 149 (16.8%) of the women 
with GDM + non-PCOS were treated with insulin during 
pregnancy (P = 0.022) (Table  1). The difference between 
the groups was related to higher BMI (P = 0.056).
Discussion
In this case–control study, self-reported symptoms 
and/or prior diagnosis of PCOS was not an independent 
risk factor for GDM. Indeed, the prevalence of GDM was 
higher in women with PCOS than in women without 
PCOS, but the difference was mediated by maternal 
Table 1 Characteristics of participants in each subgroup (n = 1941).
 
 
Characteristic
Mean (s.d.)/n (%)  
 
No. missing
GDM + PCOS 
(n = 105)
GDM + non-PCOS 
(n = 909)
Non-GDM + PCOS 
(n = 69)
Controls 
(n = 858)
Participants’ birtha
 Birth weight (g) 3323 (570) 3392 (559) 3511 (474) 3471 (505) 7/77/8/58
 s.d. score for birth weight −0.35 (1.16) −0.14 (1.07) 0.04 (1.00) 0.02 (1.02) 20/192/14/167
 Gestational age (weeks) 39.7 (1.7) 39.7 (2.2) 40.3 (1.5) 39.8 (1.8) 17/194/11/159
  <37 + 0 weeks (%) 4 (4.5) 46 (6.4) 0 23 (3.3) 17/194/11/159
 SGAb (%) 6 (7.1) 24 (3.3) 1 (1.8) 15 (2.2) 20/192/14/167
 LGAc (%) 0 21 (2.9) 1 (1.8) 19 (2.7) 20/192/14/167
Participants’ educational attainmenta
 Basic or less (%) 4 (3.8) 62 (6.8) 1 (1.4) 41 (4.8)
 Secondary (%) 39 (37.1) 437 (48.1) 27 (39.1) 394 (45.9)
 Lower-level tertiary (%) 45 (42.9) 223 (24.5) 19 (27.5) 210 (24.5)
 Upper-level tertiary (%) 17 (16.2) 187 (20.6) 22 (31.9) 213 (24.8)
Participants’ current characteristics
 Age at delivery (years) 32.0 (5.0) 31.5 (5.4) 29.9 (3.8) 28.8 (5.1)
 Height (cm) 164.9 (5.9) 164.7 (5.8) 166.2 (6.1) 165.3 (5.9)
 Weight (kg) 80.8 (18.6) 75.9 (17.0) 67.8 (14.9) 64.7 (12.3)
 Pre-pregnancy BMI (kg/m2) 29.7 (6.6) 27.9 (5.9) 24.5 (5.1) 23.6 (4.1)
 Smoking habit, n (%) 1/2/0/1
  Before and during pregnancy (%) 16 (15.4) 144 (15.9) 13 (18.8) 127 (14.8)
  Before but not during pregnancy (%) 10 (9.6) 137 (15.1) 8 (11.6) 122 (14.2)
  Not at all (%) 78 (75.0) 623 (68.7) 48 (69.6) 607 (70.8)
 Number of previous pregnancies
  0 (%) 35 (33.3) 272 (29.9) 29 (42.0) 341 (39.7)
  1 (%) 23 (21.9) 246 (27.1) 23 (33.3) 216 (25.2)
  2 (%) 17 (16.2) 153 (16.8) 5 (7.2) 123 (14.3)
  3 or more (%) 30 (28.6) 238 (26.2) 12 (17.4) 178 (20.8)
 Number of previous deliveries
  0 (%) 44 (41.9) 388 (42.7) 38 (55.1) 433 (50.5)
  1 (%) 40 (38.1) 254 (27.9) 18 (26.1) 212 (24.7)
  2 (%) 11 (10.5) 118 (13.0) 8 (11.6) 102 (11.9)
  3 or more (%) 10 (9.5) 149 (16.4) 5 (7.2) 111 (12.9)
 Insulin-treated GDM, n (%) 27 (26.0) 149 (16.8) 1/21
 Metformin-treated GDM, n (%) 4 (3.8) 21 (2.4) 1/21
 Diet-treated GDM, n (%) 73 (70.2) 718 (83.2) 1/21
aAs reported by the participants at recruitment in this study; bsmall for gestational age (<−2 s.d.); clarge for gestational age (>+2 s.d.).
GDM, gestational diabetes mellitus; PCOS, polycystic ovary syndrome; s.d., standard deviation.
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adiposity and higher age rather than by the syndrome 
itself. As expected, GDM was predicted by a family 
history of GDM and T2D. This finding seemed to be 
similar for participants with GDM regardless of PCOS 
status.
Several studies have shown that PCOS is an 
independent risk factor for GDM (2, 15, 16, 17, 18). In 
the present study, however, we found that obesity is 
the most important risk factor for GDM in women with 
PCOS. In line with this result, in a previous Finnish 
study, overweight was the strongest predictor for 
GDM, although PCOS slightly increased the risk (19). 
Furthermore, other studies did not find an increased 
risk for GDM in non-obese women with PCOS or when 
participants were matched according to BMI and age (20, 
21, 22). Possible reasons for these discordant results may 
be differences in diagnostic criteria and heterogeneous 
study populations. In the present study, PCOS women 
without GDM were significantly leaner than women 
with GDM, and their mean BMI was similar to the BMI 
of the controls, which may explain the findings. This 
result is also in keeping with the findings of a recent 
large Finnish cohort study in which only overweight and 
obese women with PCOS were at risk for subsequent T2D 
(31). These results suggest that obese women with PCOS 
are at substantial risk for GDM and should, therefore, 
be recognised and counselled as a high-risk group before 
or during the early stages of pregnancy to achieve more 
efficient therapeutic interventions. Inversely, the present 
findings challenge the utility of a routine OGTT during 
early pregnancy in women with PCOS in the absence of 
other risk factors.
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Table 3 Crude and adjusted odds ratios (ORs) for risk factors 
of gestational diabetes mellitus (GDM) calculated by logistic 
regression (n = 2212).
Risk factor Crude OR Adjusted ORa
Own preterm birthb 2.10 (1.27–3.48) 2.32 (1.34–4.03)
PCOS 1.44 (1.05–1.97) 1.07 (0.74–1.54)
BMI ≥25 kg/m2 4.87 (4.07–5.84) 4.22 (3.44–5.18)
BMI ≥30 kg/m2 5.47 (4.26–7.02) 5.14 (3.87–6.83)
Age ≥35 years 2.34 (1.90–2.88) 2.58 (1.98–3.38)
Participant’s mother’s 
GDM
2.43 (1.62–3.65) 3.05 (1.93–4.82)
Participant’s mother’s 
T2D
2.64 (1.92–3.62) 1.85 (1.30–2.64)
Participant’s father’s T2D 1.77 (1.37–2.28) 1.37 (1.03–1.83)
aLogistic regression for categorical variables adjusted for participants’ 
parity, smoking during pregnancy, educational attainment, delivery 
hospital, age and pre-pregnancy BMI; bparticipant born <37 + 0 weeks of 
gestation.
PCOS, polycystic ovary syndrome; T2D, type 2 diabetes.
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In addition to overweight and obesity, age and a 
family history of diabetes were significant risk factors 
for GDM, as expected and in line with the results 
of previous studies (32, 33, 34). In particular, if a 
participant’s mother had a history of GDM or T2D, 
the participant’s risk for GDM increased two- to three-
fold, in accordance with previous data (35, 36, 37). 
Also, father’s history of T2D increased the participant’s 
risk of GDM. In the present study, the risk remained 
elevated even after adjusting for participants’ BMI, 
suggesting that genetic factors may play a strong role 
in the development of GDM in addition to lifestyle and 
environmental conditions.
Interestingly, 7% of participants with GDM + PCOS 
were born SGA, which was three times that of the 
control group. Additionally, the participants with GDM, 
regardless of their PCOS status, were twice as likely 
to be born preterm. These women were also slightly 
shorter than controls, in line with previous reports 
showing a 1.9–3.0 cm height difference, which may be 
explained by genetic, hormonal or nutritional issues 
as well as by socio-economic issues (38, 39, 40). Due 
to the relatively small sample sizes, our results must 
be interpreted with caution, but they are consistent 
with earlier observations that low birth weight and 
preterm birth increase an individual’s risk of GDM 
Figure 3
Prevalence of normal weight, overweight and 
obese women in the subgroups. P values for 
difference between each subgroup and the 
control group: *<0.05; **<0.001. P value for 
difference between GDM + PCOS group and 
GDM + non-PCOS group: §0.009. Normal weight 
BMI: 18.5–24.9 kg/m2, overweight BMI:  
25.0–29.9 kg/m2 and obese BMI: ≥30.0 kg/m2.
Table 4 Participants’ parents’ education and medical histories categorised by subgroup (n = 1941).
 
 
Characteristic
Mean (s.d.)/n (%)  
 
No. missing
GDM + PCOS 
(n = 105)
GDM + non-PCOS 
(n = 909)
Non-GDM  + PCOS 
(n = 69) Controls (n = 858)
Education of participants’ parentsa
 Highest education of either parent 1/14/0/6
  Basic or less (%) 25 (24.0) 188 (21.0) 10 (14.5) 142 (16.7)
  Secondary (%) 61 (58.7) 526 (58.8) 42 (60.9) 465 (54.3)
  Lower-level tertiary (%) 6 (5.8) 61 (6.8) 7 (10.1) 86 (10.1)
  Upper-level tertiary (%) 12 (11.5) 120 (13.4) 10 (14.5) 161 (18.9)
Medical history of participants’ parentsa
 Pregnancy history of participants’ mothers
  GDMb (%) 2 (2.2) 25 (3.1) 1 (1.5) 13 (1.6) 4/92/14/55
  GDM at any pregnancy (%) 6 (5.9) 80 (9.3) 2 (3.2) 32 (4.0) 3/47/7/48
  Pre-eclampsiab (%) 7 (7.9) 46 (5.4) 1 (1.5) 35 (4.4) 16/75/4/64
 Medical history of participants’ mothers
  Diabetes mellitus (%) 16 (15.5) 136 (15.4) 6 (9.5) 52 (6.3) 2/25/6/27
  Hypertension (%) 27 (27.0) 255 (29.0) 13 (20.3) 180 (21.8) 5/31/5/34
  Myocardial infarction (%) 2 (2.0) 13 (1.5) 2 (3.2) 15 (1.8) 3/26/6/27
  Stroke (%) 1 (1.0) 26 (2.9) 4 (6.3) 14 (1.7) 4/23/5/28
 Medical history of participants’ fathers
  Diabetes mellitus (%) 25 (24.8) 159 (18.5) 8 (13.1) 99 (12.0) 4/48/8/34
  Hypertension (%) 28 (28.9) 247 (29.4) 18 (30.0) 177 (21.8) 8/70/9/45
  Myocardial infarction (%) 11 (11.2) 91 (10.6) 5 (8.3) 79 (9.6) 7/50/9/36
  Stroke (%) 3 (3.1) 47 (5.5) 2 (3.4) 30 (3.6) 7/47/10/36
aAs reported by the participants at recruitment in this study; bduring the pregnancy when the study participant was born.
GDM, gestational diabetes mellitus; PCOS, polycystic ovary syndrome.
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(41, 42). Preterm birth is also a well-established risk 
factor for T2D and related cardiometabolic risk factors 
(43, 44, 45). Moreover, the catch-up growth of SGA 
children is associated with insulin resistance in 
childhood (46, 47).
To the best of our knowledge, this is the first study 
comparing women with GDM, PCOS or both with 
controls in a population-based data set. Importantly, in 
this large, well-defined nationwide and homogenous 
study population (99.8% of Caucasian origin), we 
were able to take into account most of the potential 
confounders. An important limitation of the study is that 
the definition of PCOS was based on a questionnaire, since 
the study setting did not allow a clinical examination of 
the participants and the diagnosis of PCOS could not be 
made during pregnancy. Though hirsutism is subjective 
and may easily be over-reported, we have previously 
shown that self-reported isolated hirsutism does correlate 
with increased androgen secretion and that self-reported 
oligomenorrhoea and hirsutism can identify women with 
the typical endocrine and metabolic profiles of PCOS 
(25, 26). The participants’ reports of prior PCOS diagnoses 
made by a physician could not be verified from the 
medical records, which may increase the heterogeneity 
of the study population and the presence of mild states 
of PCOS. However, the results were congruent regardless 
of whether the definition of PCOS was based on symptoms 
or self-report. Finally, all women with PCOS participating 
in the present study had become pregnant and delivered, 
which may also indicate a milder disorder and a more 
favourable metabolic profile compared with women who 
did not become pregnant. This issue may have decreased 
the incidence of GDM in the subgroup of women 
with PCOS.
We conclude that PCOS is not an independent risk 
factor for GDM and that the increased risk of GDM in 
women with PCOS is mainly related to adiposity. In 
particular, obese women with PCOS are at substantial 
risk for GDM and often need insulin treatment during 
pregnancy. Therefore, they should be recognised and 
counselled as a high-risk group before or during the early 
stages of pregnancy to achieve more efficient therapeutic 
interventions. Inversely, the utility of a routine early 
OGTT during pregnancy in PCOS women in the absence 
of other risk factors should be reconsidered. Last, a 
family history of GDM or T2D, elevated maternal age 
over 35 years and own preterm birth should be noted as 
risk factors for GDM. These actions could help identify 
individuals at risk for GDM and focus on preventive 
measures.Ta
b
le
 5
 
C
ru
d
e 
an
d
 a
d
ju
st
ed
a  
o
d
d
s 
ra
ti
o
s 
(O
R
s)
 o
f 
th
e 
m
ed
ic
al
 h
is
to
ri
es
 o
f 
th
e 
p
ar
en
ts
 o
f 
w
o
m
en
 w
it
h
 p
o
ly
cy
st
ic
 o
va
ry
 s
yn
d
ro
m
e 
(P
C
O
S)
 a
n
d
 g
es
ta
ti
o
n
al
 d
ia
b
et
es
 
m
el
lit
u
s 
(G
D
M
) 
o
r 
b
o
th
 c
o
m
p
ar
ed
 w
it
h
 h
ea
lt
h
y 
co
n
tr
o
ls
 (
n
 =
 1
94
1)
.
  C
h
a
ra
ct
e
ri
st
ic
O
R
 (
95
%
 C
I)
G
D
M
 +
 P
C
O
S 
(n
 =
 1
05
)
G
D
M
 +
 n
o
n
-P
C
O
S 
(n
 =
 9
09
)
N
o
n
-G
D
M
 +
 P
C
O
S 
(n
 =
 6
9)
C
ru
d
e
A
d
ju
st
ed
a
C
ru
d
e
A
d
ju
st
ed
a
C
ru
d
e
A
d
ju
st
ed
a
Pr
eg
n
an
cy
 h
is
to
ry
 o
f 
p
ar
ti
ci
p
an
ts
’ m
o
th
er
sb
 
G
D
M
c
1.
37
 (
0.
30
–6
.1
5)
1.
80
 (
0.
34
–9
.4
4)
1.
92
 (
0.
97
–3
.7
8)
1.
86
 (
0.
89
–3
.9
1)
0.
95
 (
0.
12
–7
.3
8)
0.
98
 (
0.
12
–7
.6
8)
 
G
D
M
 a
t 
an
y 
p
re
g
n
an
cy
1.
52
 (
0.
62
–3
.7
3)
2.
30
 (
0.
82
–6
.4
8)
2.
49
 (
1.
63
–3
.7
9)
3.
25
 (
2.
04
–5
.1
8)
0.
81
 (
0.
19
–3
.4
6)
0.
95
 (
0.
22
–4
.1
5)
 
Pr
e-
ec
la
m
p
si
ac
1.
85
 (
0.
80
–4
.3
0)
1.
48
 (
0.
58
–3
.7
5)
1.
27
 (
0.
81
–1
.9
9)
0.
94
 (
0.
57
–1
.5
5)
0.
34
 (
0.
05
–2
.5
1)
0.
27
 (
0.
04
–2
.0
0)
M
ed
ic
al
 h
is
to
ry
 o
f 
p
ar
ti
ci
p
an
ts
’ m
o
th
er
sb
 
D
ia
b
et
es
 m
el
lit
u
s
2.
76
 (
1.
51
–5
.0
3)
2.
16
 (
1.
06
–4
.4
0)
2.
72
 (
1.
95
–3
.8
1)
1.
87
 (
1.
29
–2
.7
2)
1.
58
 (
0.
65
–3
.8
3)
1.
41
 (
0.
57
–3
.4
6)
 
H
yp
er
te
n
si
o
n
1.
32
 (
0.
83
–2
.1
2)
1.
27
 (
0.
74
–2
.1
6)
1.
46
 (
1.
13
–1
.8
3)
1.
23
 (
0.
96
–1
.5
7)
0.
91
 (
0.
49
–1
.7
1)
0.
90
 (
0.
48
–1
.7
2)
 
M
yo
ca
rd
ia
l i
n
fa
rc
ti
o
n
1.
09
 (
0.
25
–4
.8
3)
0.
39
 (
0.
06
–2
.5
9)
0.
81
 (
0.
38
–1
.7
2)
0.
43
 (
0.
18
–1
.0
4)
1.
78
 (
0.
40
–7
.9
8)
1.
27
 (
0.
27
–5
.9
6)
 
St
ro
ke
0.
58
 (
0.
08
–4
.4
8)
0.
78
 (
0.
09
–6
.7
9)
1.
76
 (
0.
91
–3
.4
0)
1.
36
 (
0.
65
–2
.8
3)
3.
89
 (
1.
24
–1
2.
2)
3.
74
 (
1.
16
–1
2.
0)
M
ed
ic
al
 h
is
to
ry
 o
f 
p
ar
ti
ci
p
an
ts
’ f
at
h
er
sb
 
D
ia
b
et
es
 m
el
lit
u
s
2.
41
 (
1.
46
–3
.9
7)
1.
76
 (
0.
99
–3
.1
1)
1.
66
 (
1.
26
–2
.1
8)
1.
26
 (
0.
94
–1
.7
1)
1.
11
 (
0.
51
–2
.3
9)
1.
03
 (
0.
47
–2
.2
6)
 
H
yp
er
te
n
si
o
n
1.
46
 (
0.
91
–2
.3
3)
1.
36
 (
0.
80
–2
.3
0)
1.
50
 (
1.
20
–1
.8
7)
1.
22
 (
0.
95
–1
.5
7)
1.
54
 (
0.
87
–2
.7
4)
1.
46
 (
0.
81
–2
.6
2)
 
M
yo
ca
rd
ia
l i
n
fa
rc
ti
o
n
1.
19
 (
0.
61
–2
.3
2)
0.
80
 (
0.
36
–1
.7
8)
1.
11
 (
0.
81
–1
.5
3)
0.
86
 (
0.
60
–1
.2
3)
0.
86
 (
0.
33
–2
.2
0)
0.
88
 (
0.
34
–2
.2
8)
 
St
ro
ke
0.
83
 (
0.
25
–2
.7
8)
0.
82
 (
0.
20
–3
.4
3)
1.
52
 (
0.
95
–2
.4
3)
1.
50
 (
0.
88
–2
.5
4)
0.
93
 (
0.
22
–3
.9
7)
1.
05
 (
0.
24
–4
.5
6)
a L
o
g
is
ti
c 
re
g
re
ss
io
n
 f
o
r 
ca
te
g
o
ri
ca
l v
ar
ia
b
le
s 
ad
ju
st
ed
 f
o
r 
p
ar
ti
ci
p
an
ts
’ p
ar
it
y,
 s
m
o
ki
n
g
 d
u
ri
n
g
 p
re
g
n
an
cy
, e
d
u
ca
ti
o
n
al
 a
tt
ai
n
m
en
t,
 d
el
iv
er
y 
h
o
sp
it
al
, a
g
e 
an
d
 p
re
-p
re
g
n
an
cy
 B
M
I; 
b
as
 r
ep
o
rt
ed
 b
y 
th
e 
p
ar
ti
ci
p
an
ts
 a
t 
re
cr
u
it
m
en
t 
in
 t
h
is
 s
tu
d
y;
 c d
u
ri
n
g
 t
h
e 
p
re
g
n
an
cy
 w
h
en
 t
h
e 
st
u
d
y 
p
ar
ti
ci
p
an
t 
w
as
 b
o
rn
.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0076
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
S Mustaniemi et al. PCOS and risk factors for 
gestational diabetes
8687:7
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
This work was supported by Academy of Finland (grant numbers 127437, 
128929, 129306, 130326, 134791, 274794); Foundation for Pediatric 
Research; Diabetes Research Foundation; Juho Vainio Foundation; Novo 
Nordisk Foundation; Signe and Ane Gyllenberg Foundation; Sigrid Jusélius 
Foundation and Yrjö Jahnsson Foundation.
Authors’ contribution statement
M V, H L, J G E, M G, E K and L C M-P designed the FinnGeDi study and 
contributed to data collection. M V, E K, S M and L C M-P designed the 
present study. A B participated in data management. S M participated 
in data collection, cleaning and analysis. S M and E K performed data 
analysis and M V, H L, J G E, H I, M G, A B and L C M-P contributed to its 
interpretation. S M wrote the first draft of the manuscript and L C M-P, 
M V and E K reviewed, completed and supervised the manuscript writing. 
All authors read and approved the final manuscript.
Acknowledgements
The authors thank all the participants of the study, data extractors 
Riitta Kokko, Jenni Kovalainen, Saara Peuhkuri, Susanna Hamari, 
Hanna Valtonen, Sanni Paloviita, Raili Voittonen and Anu Ojala, nurse 
coordinator Tiina Kemppainen and research nurse Sarianna Vaara for help 
with practical arrangements and participating hospitals.
References
 1 Norman RJ, Dewailly D, Legro RS & Hickey TE. Polycystic ovary 
syndrome. Lancet 2007 370 685–697. (https://doi.org/10.1016/
S0140-6736(07)61345-2)
 2 Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H & 
Stephansson O. Risk of adverse pregnancy outcomes in women with 
polycystic ovary syndrome: population-based cohort study. BMJ 2011 
343 d6309. (https://doi.org/10.1136/bmj.d6309)
 3 Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, 
Metzger BE, Lowe LP, Coustan DR, Hod M, Oats JJ, et al. Frequency 
of gestational diabetes mellitus at collaborating centres based on 
IADPSG consensus panel-recommended criteria: the Hyperglycemia 
and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care 2012 
35 526–528. (https://doi.org/10.2337/dc11-1641)
 4 Helseth R, Vanky E, Salvesen Ø & Carlsen SM. Gestational diabetes 
mellitus among Norwegian women with polycystic ovary syndrome: 
prevalence and risk factors according to the WHO and the modified 
IADPSG criteria. European Journal of Endocrinology 2013 169 65–72. 
(https://doi.org/10.1530/EJE-12-1107)
 5 Koivunen S, Kajantie E, Torkki A, Bloigu A, Gissler M, Pouta A & 
Vääräsmäki M. The changing face of gestational diabetes: the effect 
of the shift from risk factor-based to comprehensive screening. 
European Journal of Endocrinology 2015 173 623–632. (https://doi.
org/10.1530/EJE-15-0294)
 6 Bhathena RK. Insulin resistance and the long-term consequences of 
polycystic ovary syndrome. Journal of Obstetrics and Gynaecology 2011 
31 105–110. (https://doi.org/10.3109/01443615.2010.539722)
 7 Hildén K, Hanson U, Persson M & Fadl H. Overweight and obesity: a 
remaining problem in women treated for severe gestational diabetes. 
Diabetic Medicine 2016 33 1045–1051. (https://doi.org/10.1111/
dme.13156)
 8 Vink JM, Sadrzadeh S, Lambalk CB & Boomsma DI. Heritability of 
polycystic ovary syndrome in a Dutch twin-family study. Journal of 
Clinical Endocrinology and Metabolism 2006 91 2100–2104. (https://
doi.org/10.1210/jc.2005-1494)
 9 Lowe WL Jr, Scholtens DM, Sandler V & Hayes MG. Genetics of 
gestational diabetes mellitus and maternal metabolism. Current 
Diabetes Reports 2016 16 15. (https://doi.org/10.1007/s11892-015-
0709-z)
 10 Goueslard K, Cottenet J, Mariet AS, Giroud M, Cottin Y, Petit JM & 
Quantin C. Early cardiovascular events in women with a history of 
gestational diabetes mellitus. Cardiovascular Diabetology 2016 15 15. 
(https://doi.org/10.1186/s12933-016-0338-0)
 11 Palomba S, Falbo A, Russo T, Rivoli L, Orio M, Cosco AG, Vero R, 
Capula C, Tolino A, Zullo F, et al. The risk of a persistent glucose 
metabolism impairment after gestational diabetes mellitus is 
increased in patients with polycystic ovary syndrome. Diabetes Care 
2012 35 861–867. (https://doi.org/10.2337/dc11-1971)
 12 Ijäs H, Morin-Papunen L, Keränen AK, Bloigu R, Ruokonen A, 
Puukka K, Ebeling T, Raudaskoski T & Vääräsmäki M. Pre-pregnancy 
overweight overtakes gestational diabetes as a risk factor for 
subsequent metabolic syndrome. European Journal of Endocrinology 
2013 169 605–611. (https://doi.org/10.1530/EJE-13-0412)
 13 Joham AE, Ranasinha S, Zoungas S, Moran L & Teede HJ. Gestational 
diabetes and type 2 diabetes in reproductive-aged women with 
polycystic ovary syndrome. Journal of Clinical Endocrinology and 
Metabolism 2014 99 E447–E452. (https://doi.org/10.1210/jc.2013-2007)
 14 Hakkarainen H, Huopio H, Cederberg H, Pääkkönen M, 
Voutilainen R & Heinonen S. The risk of metabolic syndrome in 
women with previous GDM in a long-term follow-up. Gynecological 
Endocrinology 2016 32 920–925. (https://doi.org/10.1080/09513590.2
016.1198764)
 15 Rees DA, Jenkins-Jones S & Morgan CL. Contemporary reproductive 
outcomes for patients with polycystic ovary syndrome: a 
retrospective observational study. Journal of Clinical Endocrinology and 
Metabolism 2016 101 1664–1672. (https://doi.org/10.1210/jc.2015-
2682)
 16 Mumm H, Jensen DM, Sørensen JA, Andersen LL, Ravn P, 
Andersen M & Glintborg D. Hyperandrogenism and phenotypes of 
polycystic ovary syndrome are not associated with differences in 
obstetric outcomes. Acta Obstetricia et Gynecologica Scandinavica 2015 
94 204–211. (https://doi.org/10.1111/aogs.12545)
 17 Radon PA, McMahon MJ & Meyer WR. Impaired glucose tolerance 
in pregnant women with polycystic ovary syndrome. Obstetrics and 
Gynecology 1999 94 194–197.
 18 Reyes-Muñoz E, Castellanos-Barroso G, Ramírez-Eugenio BY, 
Ortega-González C, Parra A, Castillo-Mora A & De la Jara-Díaz JF. 
The risk of gestational diabetes mellitus among Mexican women 
with a history of infertility and polycystic ovary syndrome. 
Fertility and Sterility 2012 97 1467–1471. (https://doi.org/10.1016/j.
fertnstert.2012.03.023)
 19 Mikola M, Hiilesmaa V, Halttunen M, Suhonen L & Tiitinen A. 
Obstetric outcome in women with polycystic ovarian syndrome. 
Human Reproduction 2001 16 226–229. (https://doi.org/10.1093/
humrep/16.2.226)
 20 Han AR, Kim HO, Cha SW, Park CW, Kim JY, Yang KM, Song IO, 
Koong MK & Kang IS. Adverse pregnancy outcomes with assisted 
reproductive technology in non-obese women with polycystic 
ovary syndrome: a case-control study. Clinical and Experimental 
Reproductive Medicine 2011 38 103–108. (https://doi.org/10.5653/
cerm.2011.38.2.103)
 21 Haakova L, Cibula D, Rezabek K, Hill M, Fanta M & Zivny J. 
Pregnancy outcome in women with PCOS and in controls matched 
by age and weight. Human Reproduction 2003 18 1438–1441. (https://
doi.org/10.1093/humrep/deg289)
 22 Turhan NÖ, Seçkin NC, Aybar F & Inegöl I. Assessment of glucose 
tolerance and pregnancy outcome of polycystic ovary patients. 
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0076
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
S Mustaniemi et al. PCOS and risk factors for 
gestational diabetes
8697:7
International Journal of Gynaecology and Obstetrics 2003 81 163–168. 
(https://doi.org/10.1016/S0020-7292(03)00003-1)
 23 Finnish Medical Society Duodecim. Current Care Guidelines for 
Gestational Diabetes. Helsinki, Finland: The Finnish Medical Society 
Duodecim, 2008. (available at: www.kaypahoito.fi)
 24 Koivunen S, Torkki A, Bloigu A, Gissler M, Pouta A, Kajantie E & 
Vääräsmäki M. Towards national comprehensive gestational diabetes 
screening – consequences for neonatal outcome and care. Acta 
Obstetricia et Gynecologica Scandinavica 2016 96 106–113. (https://doi.
org/10.1111/aogs.13030)
 25 Taponen S, Martikainen H, Järvelin MR, Laitinen J, Pouta A, 
Hartikainen AL, Sovio U, McCarthy MI, Franks S & Ruokonen A. 
Hormonal profile of women with self-reported symptoms of 
oligomenorrhea and/or hirsutism: Northern Finland birth cohort 
1966 study. Journal of Clinical Endocrinology and Metabolism 2003 88 
141–147. (https://doi.org/10.1210/jc.2002-020982)
 26 Taponen S, Ahonkallio S, Martikainen H, Koivunen R, Ruokonen A, 
Sovio U, Hartikainen AL, Pouta A, Laitinen J, King V, et al. Prevalence 
of polycystic ovaries in women with self-reported symptoms of 
oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 
1966 Study. Human Reproduction 2004 19 1083–1088. (https://doi.
org/10.1093/humrep/deh214)
 27 Pihkala J, Hakala T, Voutilainen P & Raivio K. Characteristic of 
recent fetal growth curves in Finland. Duodecim; Lääketieteellinen 
Aikakauskirja 1989 105 1540–1546.
 28 World Health Organization. Obesity: preventing and managing 
the global epidemic. Report of a WHO consultation. World Health 
Organization Technical Report Series 2000 894 1–253.
 29 Merkin SS, Azziz R, Seeman T, Calderon-Margalit R, Daviglus M, 
Kiefe C, Matthews K, Sternfeld B & Siscovick D. Socioeconomic status 
and polycystic ovary syndrome. Journal of Women’s Health 2011 20 
413–419. (https://doi.org/10.1089/jwh.2010.2303)
 30 England LJ, Levine RJ, Qian C, Soule LM, Schisterman EF, Yu KF 
& Catalano PM. Glucose tolerance and risk of gestational diabetes 
mellitus in nulliparous women who smoke during pregnancy. 
American Journal of Epidemiology 2004 160 1205–1213. (https://doi.
org/10.1093/aje/kwh340)
 31 Ollila ME, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, 
Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, Franks S, et al. 
Overweight and obese but not normal weight women with PCOS 
are at increased risk of Type 2 diabetes mellitus-a prospective, 
population-based cohort study. Human Reproduction 2017 32 
423–431. (https://doi.org/10.1093/humrep/dew329)
 32 Kun A, Tornóczky J & Tabák AG. The prevalence and predictors of 
gestational diabetes mellitus in Hungary. Hormone and Metabolic 
Research 2011 43 788–793. (https://doi.org/10.1055/s-0031-1287795)
 33 Savvidou M, Nelson SM, Makgoba M, Messow CM, Sattar N & 
Nicolaides K. First-trimester prediction of gestational diabetes 
mellitus: examining the potential of combining maternal 
characteristics and laboratory measures. Diabetes 2010 59 3017–3022. 
(https://doi.org/10.2337/db10-0688)
 34 Teh WT, Teede HJ, Paul E, Harrison CL, Wallace EM & Allan C. 
Risk factors for gestational diabetes mellitus: implications for the 
application of screening guidelines. Australian and New Zealand 
Journal of Obstetrics and Gynaecology 2011 51 26–30. (https://doi.
org/10.1111/j.1479-828X.2011.01292.x)
 35 Moosazadeh M, Asemi Z, Lankarani KB, Tabrizi R, Maharlouei N, 
Naghibzadeh-Tahami A, Yousefzadeh G, Sadeghi R, Khatibi SR, 
Afshari M, et al. Family history of diabetes and the risk of gestational 
diabetes mellitus in Iran: a systematic review and meta-analysis. 
Diabetes and Metabolic Syndrome 2017 11 (Supplement 1) S99–S104. 
(https://doi.org/10.1016/j.dsx.2016.12.016)
 36 Syngelaki A, Pastides A, Kotecha R, Wright A, Akolekar R & 
Nicolaides KH. First-trimester screening for gestational diabetes 
mellitus based on maternal characteristics and history. Fetal Diagnosis 
and Therapy 2015 38 14–21. (https://doi.org/10.1159/000369970)
 37 van Leeuwen M, Opmeer BC, Zweers EJ, van Ballegooie E, ter 
Brugge HG, de Valk HW, Visser GH & Mol BW. Estimating the risk 
of gestational diabetes mellitus: a clinical prediction model based on 
patient characteristics and medical history. BJOG 2010 117 69–75. 
(https://doi.org/10.1111/j.1471-0528.2009.02425.x)
 38 Anastasiou E, Alevizaki M, Grigorakis SJ, Philippou G, Kyprianou M 
& Souvatzoglou A. Decreased stature in gestational diabetes 
mellitus. Diabetologia 1998 41 997–1001. (https://doi.org/10.1007/
s001250051022)
 39 Kousta E, Lawrence NJ, Penny A, Millauer BA, Robinson S, 
Johnston DG & McCarthy MI. Women with a history of gestational 
diabetes of European and South Asian origin are shorter than 
women with normal glucose tolerance in pregnancy. Diabetic 
Medicine 2000 17 792–797. (https://doi.org/10.1046/j.1464-
5491.2000.00393.x)
 40 Ogonowski J & Miazgowski T. Are short women at risk for gestational 
diabetes mellitus? European Journal of Endocrinology 2010 162 
491–497. (https://doi.org/10.1530/EJE-09-0992)
 41 Boivin A, Luo ZC, Audibert F, Mâsse B, Lefebvre F, Tessier R & 
Nuyt AM. Pregnancy complications among women born preterm. 
Canadian Medical Association Journal 2012 184 1777–1784. (https://
doi.org/10.1503/cmaj.120143)
 42 Innes KE, Byers TE, Marshall JA, Barón A, Orleans M & Hamman RF. 
Association of a woman’s own birth weight with subsequent risk 
for gestational diabetes. JAMA 2002 287 2534–2541. (https://doi.
org/10.1001/jama.287.19.2534)
 43 Hovi P, Andersson S, Eriksson JG, Järvenpää AL, Strang-Karlsson S, 
Mäkitie O & Kajantie E. Glucose regulation in young adults with 
very low birth weight. New England Journal of Medicine 2007 356 
2053–2063. (https://doi.org/10.1056/NEJMoa067187)
 44 Kajantie E & Hovi P. Is very preterm birth a risk factor for adult 
cardiometabolic disease? Seminars in Fetal and Neonatal Medicine 2014 
19 112–117. (https://doi.org/10.1016/j.siny.2013.11.006)
 45 Sipola-Leppänen M, Vääräsmäki M, Tikanmäki M, Matinolli HM, 
Miettola S, Hovi P, Wehkalampi K, Ruokonen A, Sundvall J, Pouta A, 
et al. Cardiometabolic risk factors in young adults who were born 
preterm. American Journal of Epidemiology 2015 181 861–873. (https://
doi.org/10.1093/aje/kwu443)
 46 Ibáñez L, Ong K, Dunger DB & de Zegher F. Early development of 
adiposity and insulin resistance after catch-up weight gain in small-
for-gestational-age children. Journal of Clinical Endocrinology and 
Metabolism 2006 91 2153–2158. (https://doi.org/10.1210/jc.2005-
2778)
 47 Liu C, Wu B, Lin N & Fang X. Insulin resistance and its association 
with catch-up growth in Chinese children born small for gestational 
age. Obesity 2017 25 172–177. (https://doi.org/10.1002/oby.21683)
Received in final form 19 April 2018
Accepted 31 May 2018
Accepted Preprint published online 1 June 2018
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0076
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
